Alembic Pharmaceuticals Limited (APLLTD) — Announcement | 10 August 2026 (2 announcements)

Alembic Pharmaceuticals announced the resignation of Company Secretary and Compliance Officer Manisha Saraf effective August 10, 2026, as per SEBI Regulation 30 disclosures. The filing includes her resignation letter and regulatory requirements for record-keeping with stock exchanges.

Alembic Pharmaceuticals reported 26% YoY revenue growth to INR2,150 crores in Q1 FY27, driven by 37% growth in International Generics and 49% growth in US Generics, with new product launches and US Branded expansion accelerating momentum. Management upgraded FY27 growth outlook to mid-teens, targeting breakeven by Q4 FY27 while accepting ~150 bps margin dilution from US Branded investments, supported by INR186 crores R&D spend (9% of revenue) and expansion into new markets like Latin America.